Edition:
United Kingdom

Tocagen Inc (TOCA.OQ)

TOCA.OQ on NASDAQ Stock Exchange Global Select Market

11.88USD
14 Dec 2017
Change (% chg)

$0.88 (+8.00%)
Prev Close
$11.00
Open
$11.10
Day's High
$12.17
Day's Low
$11.10
Volume
101,128
Avg. Vol
41,045
52-wk High
$17.75
52-wk Low
$8.64

Summary

Name Age Since Current Position

Faheem Hasnain

58 2014 Independent Chairman of the Board

Martin Duvall

54 2016 Chief Executive Officer, Director

Mark Foletta

55 2017 Chief Financial Officer, Executive Vice President

Harry Gruber

64 2017 President - Science and Innovation, Director

Dennis Berman

65 2017 Executive Vice President - Corporate Development

Douglas Jolly

69 2007 Executive Vice President - Research and Pharmaceutical Development

Asha Das

52 2017 Senior Vice President, Chief Medical Officer

Thomas Darcy

66 2017 Director

Franklin Berger

67 2014 Independent Director

Lori Kunkel

59 2015 Independent Director

David Parkinson

67 2015 Independent Director

Paul Schimmel

76 2015 Independent Director

Elizabeth Broder

2016 IR Contact Officer

Biographies

Name Description

Faheem Hasnain

Mr. Faheem Hasnain serves as Independent Chairman of the Board of the Company. He has served as the Chairman of our board of directors since October 2014. Mr. Hasnain served as President, Chief Executive Officer and as a member of the board of directors of Receptos, Inc., or, Receptos, a publicly-held biopharmaceutical company, from November 2010 until the company’s acquisition by Celgene Corporation in August 2015. Prior to joining Receptos, Mr. Hasnain was the President and Chief Executive Officer and a director of Facet Biotech Corporation, or Facet Biotech, a publicly-held biology driven antibody company with a focus in multiple sclerosis and oncology. He held that position from December 2008 until the company’s acquisition by Abbott Laboratories in April 2010. Prior to joining Facet Biotech, Mr. Hasnain was President, Chief Executive Officer and a director of PDL BioPharma, Inc. from October 2008 until Facet Biotech was spun off from PDL BioPharma, Inc. in December 2008. From October 2004 to September 2008, Mr. Hasnain served at Biogen Idec Inc., a publicly-held biotechnology company specializing in neurological disorders, autoimmune disorders and cancer, most recently as Executive Vice President in charge of the oncology/rheumatology strategic business unit. Prior to Biogen Idec Inc., Mr. Hasnain held roles with Bristol Myers Squibb, where he was President of the Oncology Therapeutics Network, and for 14 years at GlaxoSmithKline and its predecessor organizations. Mr. Hasnain serves on the board of directors of Kura Oncology, Inc. and Vital Therapies, Inc. and previously served as a member of the board of directors of Ambit Biosciences Corporation, Seragon Pharmaceuticals, Inc., Tercica, Inc., Aragon Pharmaceuticals, Inc., Pernix Sleep, Inc. and Somaxon Pharmaceuticals, Inc. Mr. Hasnain received a B.H.K. and B.Ed. from the University of Windsor Ontario in Canada.

Martin Duvall

Mr. Martin J. Duvall serves as Chief Executive Officer, Director of the Company. He has served as our Chief Executive Officer and as a member of our board of directors since November 2016. Prior to joining us, Mr. Duvall served as Executive Vice President, Chief Commercial Officer of ARIAD Pharmaceuticals, Inc., a publicly-held biotechnology company, from September 2011 to June 2016. From December 2010 to September 2011, he served as Senior Vice President and General Manager for the oncology franchise at Merck & Co., Inc., a publicly-held healthcare company. Prior to that, he served in similar capacities at Abraxis Bioscience, Inc., a publicly-held biotechnology company, and MGI Pharma, Inc., a publicly-held biopharmaceutical company, and in positions of increasing responsibility at Sanofi US, a publicly-held biotechnology company. Mr. Duvall received his B.S. degree in chemistry from Muhlenberg College, his M.A. degree in chemistry from Johns Hopkins University and his M.B.A. from the University of Kansas.

Mark Foletta

Mr. Mark G. Foletta CPA serves as Chief Financial Officer, Executive Vice President of the Company. He has served as our Executive Vice President and Chief Financial Officer since February 2017. Prior to joining us, Mr. Foletta served as the Interim Chief Financial Officer of Biocept, Inc., a publicly-held diagnostics company, from August 2015 to July 2016, as an employee of Biocept, Inc. assisting with the Chief Financial Officer transition in August 2016 and as a consultant to Biocept, Inc. on a part-time basis from September 2016 to October 2016. Mr. Foletta served as Senior Vice President, Finance and Chief Financial Officer of Amylin Pharmaceuticals, Inc., or Amylin, a publicly-held biopharmaceutical company, from March 2006 until October 2012 and as Vice President, Finance and Chief Financial Officer of Amylin from March 2000 until March 2006. Mr. Foletta serves as a member of the board of directors, chairman of the audit committee and member of the nominating and governance committee of Regulus Therapeutics, Inc., a publicly-held biopharmaceutical company, as lead director of the board of directors and chairman of the audit committee of DexCom, Inc., a publicly-held medical device company and as a member of the board of directors and chairman of the audit committee of AMN Healthcare Services, Inc., a publicly-held healthcare workforce and staffing company, and Viacyte, Inc., a privately-held biotechnology company. Mr. Foletta previously served as a member of the board of directors of Ambit Biosciences Corporation and Anadys Pharmaceuticals, Inc., each a publicly-held biopharmaceutical company. Mr. Foletta received a B.A. from the University of California, Santa Barbara. He is a Certified Public Accountant (inactive) and a member of the Corporate Directors Forum.

Harry Gruber

Dr. Harry E. Gruber, M.D. serves as President - Science and Innovation, Director of the Company. He was President - Research and Development, Director of the Company. He has served as our President, Research and Development since November 2016 and as a member of our board of directors since August 2007. Dr. Gruber served as our Chief Executive Officer from August 2007 to November 2016 and served as Chairman of our board of directors from August 2007 to October 2014. Dr. Gruber is a co-founder of Tocagen and has been the co-founder and/or co-inventor of key technology for the following publicly-held companies: Gensia Inc., a biopharmaceutical company, Viagene Inc., a gene therapy company, Aramed, Inc., a biopharmaceutical company, INTERVU Inc., a technology company, and Kintera, Inc., a technology company. Dr. Gruber holds a B.A. and an M.D. from the University of Pennsylvania and trained in Internal Medicine, Biochemical Genetics and Rheumatology/Immunology at the University of California, San Diego, where he subsequently joined the medical school faculty until founding Gensia Inc.

Dennis Berman

Mr. Dennis N. Berman is Executive Vice President - Corporate Development of the Company. He has served as our Executive Vice President, Corporate Development and as a member of our board of directors since December 2007. Mr. Berman is a co-founder of Tocagen. Prior to joining us, he was an Executive Vice President, Director and co-founder of Kintera, Inc., a technology company, where he served for seven years. Prior to co-founding Kintera, Inc., Mr. Berman was Vice President of Corporate Development of INTERVU Inc., a technology company, where he oversaw strategic alliances and financings. Prior to INTERVU Inc., Mr. Berman was a partner in large law firms. Mr. Berman received his Bachelor of Arts degree from the University of Pennsylvania and his Bachelor of Science degree from The Wharton School at the University of Pennsylvania. Mr. Berman also holds a General Course Certificate from the London School of Economics and received his Juris Doctor from Harvard Law School.

Douglas Jolly

Mr. Douglas Jolly, Ph.D. serves as Executive Vice President - Research and Pharmaceutical Development of the Company. He has served as our Executive Vice President, Research and Pharmaceutical Development since December 2007. Dr. Jolly is a co-founder of Tocagen and an internationally recognized expert in the field of gene therapy and its pharmaceutical application. Over the last 25 years he has been a senior biotechnology executive involved in translating gene-based products from research through clinical development at the following companies: Viagene, Inc., where he was also a co-founder, Chiron Corporation, Oxford BioMedica plc, where he ran the U.S. subsidiary, BioMedica Inc., and Advantagene, Inc. Before entering the biopharmaceutical industry, Dr. Jolly pursued his academic career in biophysics and molecular biology at the Weizmann Institute, Harvard Medical School, Scripps Clinic, the University of California, San Diego and The French National Institute for Health and Medical Research, INSERM, in Paris, France. Dr. Jolly holds a Ph.D. in Biochemistry from the University of Glasgow. Dr. Jolly is a board member, chairman of the Industrial Liaison Committee, and also currently serves as a member of the Translational Medicine Committee, of the American Society of Gene & Cell Therapy.

Asha Das

Ms. Asha Das, M.D. serves as Senior Vice President, Chief Medical Officer of the Company. She has served as our Senior Vice President and Chief Medical Officer since March 2017 and served as our acting Chief Medical Officer from May 2016 to March 2017 and as our Vice President, Clinical Development and Medical Affairs from April 2015 to March 2017. From April 2008 to April 2015, Dr. Das served in positions of increasing responsibility at Genentech Inc., a biotechnology company and member of the Roche Group, initially as Associate Medical Director and ultimately as Group Medical Director. From 2005 to 2008, Dr. Das served as Associate Medical Director at Eisai Inc., a pharmaceutical company. Prior to that, Dr. Das was head of the neuro-oncology program at Cedars-Sinai Medical Center. Dr. Das is certified in neurology by the American Board of Psychiatry and Neurology and in the sub-specialty of neuro-oncology by the United Council for Neurologic Subspecialties and previously served as a clinical fellow in neuro-oncology at Massachusetts General Hospital. Dr. Das has completed a residency in neurology at Cornell Medical Center and has held academic appointments at the University of California, Los Angeles; University of California, San Francisco; and National University of Singapore. Dr. Das obtained her M.D. and bachelor’s degree from Cornell University.

Thomas Darcy

Mr. Thomas E. Darcy has been appointed as Director of the Company. He has served as our Executive Vice President and as a member of our board of directors since August 2007 and served as our Chief Financial Officer from August 2007 to February 2017. Mr. Darcy is a co-founder of Tocagen. Prior to joining us, Mr. Darcy served for over five years as Executive Vice President and Chief Financial Officer of Science Applications International Corporation, or SAIC, a publicly-held science and technology company. Mr. Darcy also served as a director and chairman of the audit committee of McAfee, Inc., a publicly-held technology company, for over three years until its sale to Intel Corporation in February 2011. Mr. Darcy also currently serves as a director and chairman of the audit committee of Lytx, Inc., a privately-held technology company, and the San Diego County YMCA. Prior to SAIC, he was a Partner in the accounting firm of PricewaterhouseCoopers LLP, where he served as the Managing Partner of both the West and Southwest Region Audit and Business Advisory Service Technology practices, as well as the Managing Partner of the San Diego office. Mr. Darcy is a Certified Public Accountant (inactive) in the state of California and graduated from San Diego State University with a B.S. in Accounting.

Franklin Berger

Mr. Franklin M. Berger serves as Independent Director of the Company. He has served as a member of our board of directors since October 2014. Since 2008, Mr. Berger has served as an independent consultant to biopharmaceutical companies rendering strategic and financial advice as the Managing Director of FMB Research. Mr. Berger worked at Sectoral Asset Management as a founder of the small-cap focused NEMO Fund from January 2007 through June 2008. From May 1998 to March 2003, he served at J.P. Morgan Securities Inc., most recently as Managing Director, Equity Research and Senior Biotechnology Analyst. Previously, Mr. Berger served in similar capacities at Salomon Smith Barney and Josephthal & Co. Mr. Berger also serves on the boards of directors of Immune Design Corp., BELLUS Health, Inc., ESSA Pharma Inc., Proteostasis Therapeutics, Inc. and Five Prime Therapeutics, Inc., each of which is a publicly-held biotechnology company. Mr. Berger previously served as a member of the board of directors of Seattle Genetics, Inc., Asterias Biotherapeutics, Inc. and Aurinia Pharmaceuticals, Inc., publicly-held biopharmaceutical companies, as well as Emisphere Technologies, Inc., BioTime, Inc. and VaxGen, Inc., each of which were publicly-held biopharmaceutical companies during Mr. Berger’s service as a director. Mr. Berger received his B.A. in International Relations and his M.A. in International Economics from Johns Hopkins University and received his M.B.A. from the Harvard Business School.

Lori Kunkel

Dr. Lori A. Kunkel, M.D. serves as Independent Director of the Company. She has served as a member of our board of directors since September 2015. From October 2013 to October 2014 she was the acting Chief Medical Officer of Loxo Oncology, Inc. Prior to that role she was the Chief Medical Officer of Pharmacyclics LLC, the Chief Medical Officer of Proteolix, Inc., and the Vice President of Clinical Development at Xencor, Inc., each a biopharmaceutical company. Prior to these positions she was a clinical scientist at Genentech, a biopharmaceutical company, where she worked on the development of RITUXAN. Additionally, as a clinical drug development specialist, Dr. Kunkel has advised multiple clients including Chiron, Genentech/Roche, Salmedics, and currently is an advisor to Stemcentrx, Inc. and Amphivena Therapeutics, each a biopharmaceutical company. Prior to joining the biotechnology industry, Dr. Kunkel spent ten years in academic medicine and served as a faculty member at the Bone Marrow Transplant Unit in the Division of Hematology/Oncology at University of California, Los Angeles. Dr. Kunkel serves on the board of directors of Loxo Oncology, Inc., a publicly-held biotechnology company, Curis, Inc., a publicly-held biotechnology company, and Harpoon Therapeutics, Inc., a privately-held biotechnology company. Dr. Kunkel received her medical degree from University of Southern California and her bachelor’s degree in biology from University of California, San Diego. She is board certified in internal medicine and held board certifications in hematology and oncology.

David Parkinson

Mr. David Ross Parkinson, M.D. serves as Independent Director of the Company. He has served as a member of our board of directors since April 2015. Since January 2016, Dr. Parkinson has served as the President and Chief Executive Officer of ESSA Pharma, Inc., a publicly-held biopharmaceutical company. Dr. Parkinson is also a venture advisor at New Enterprise Associates, a venture capital fund, a company he has been with since June 2012. Dr. Parkinson has more than twenty years of experience in oncology clinical development, including leading clinical activities at Amgen and Novartis for the cancer therapeutics Gleevec, Femara, Zometa, Kepivance and Vectibix. Dr. Parkinson presently serves on the board of directors of Threshold Pharmaceuticals, Cerulean Pharma Inc., ESSA Pharma Inc. and 3S Bio, each a biopharmaceutical company, and previously served on the board of directors of Facet Biotech and Ambit Biosciences Corporation, a biopharmaceutical company acquired by Daiichi Sankyo. Among other prior roles, Dr. Parkinson was Vice President of Oncology Development at Amgen, Vice President of Global Clinical Oncology Development at Novartis and Senior Vice President at Biogen Idec, leading oncology research and development. Previously, Dr. Parkinson worked at the National Cancer Institute for almost a decade, including serving as chief of the Investigational Drug Branch. He has also served as the chairman of the FDA Biologics Advisory Committee. Dr. Parkinson received his M.D. from University of Toronto Faculty of Medicine.

Paul Schimmel

Dr. Paul R. Schimmel, Ph.D. serves as Independent Director of the Company. He has served as a member of our board of directors since February 2015. Dr. Schimmel is the Hahn Professor of Molecular Biology and Chemistry at The Scripps Research Institute, a position he has held since 2001. Dr. Schimmel co-founded Alnylam Pharmaceuticals, a publicly-held biopharmaceutical company, and currently serves as a member of the company’s board of directors. He also serves as a member of the board of directors of aTyr Pharma, Inc., a publicly-held biopharmaceutical company. In addition, Dr. Schimmel co-founded and served as a founding director of Cubist Pharmaceuticals, a publicly-held biopharmaceutical company, acquired by Merck and Co. He previously served as a member of the board of directors of Alkermes plc, Sirtris Pharmaceuticals, acquired by GlaxoSmithKline, RepliGen Corporation and Momenta Pharmaceuticals, Inc., which are all publicly-held biopharmaceutical companies. Prior to joining The Scripps Research Institute, Dr. Schimmel was the MacArthur professor of biophysics and biochemistry at the Massachusetts Institute of Technology. He also served as chairman for the division of biological chemistry at the American Chemical Society and is an elected member of the American Academy of Arts and Sciences, the National Academy of Sciences, the American Philosophical Society and the Institute of Medicine. Dr. Schimmel received his Ph.D. from the Massachusetts Institute of Technology and his bachelor’s degree from Ohio Wesleyan University.

Elizabeth Broder